Last reviewed · How we verify
IOV-3001
At a glance
| Generic name | IOV-3001 |
|---|---|
| Sponsor | Iovance Biotherapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IOV-3001 CI brief — competitive landscape report
- IOV-3001 updates RSS · CI watch RSS
- Iovance Biotherapeutics, Inc. portfolio CI